Abstract

While long-term survival rates for early-stage lung cancer are high, most cases are diagnosed in later stages that can negatively impact survival rates. We aim to design a simple, single biomarker blood test for early-stage lung cancer that is robust to preclinical variables and can be readily implemented in the clinic. Whole blood was collected in PAXgene tubes from a training set of 29 patients, and a validation set of 260 patients, of which samples from 58 patients were prospectively collected in a clinical trial specifically for our study. After RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay. Elevated levels of FPR1 mRNA in whole blood predicted lung cancer status with a sensitivity of 55% and a specificity of 87% on all validation specimens. The prospectively collected specimens had a significantly higher 68% sensitivity and 89% specificity. Results from patients with benign nodules were similar to healthy volunteers. No meaningful correlation was present between our test results and any clinical characteristic other than lung cancer diagnosis. FPR1 mRNA levels in whole blood can predict the presence of lung cancer. Using this as a reflex test for positive lung cancer screening computed tomography scans has the potential to increase the positive predictive value. This marker can be easily measured in an automated process utilizing off-the-shelf equipment and reagents. Further work is justified to explain the source of this biomarker.

Original languageEnglish (US)
Pages (from-to)2355-2362
Number of pages8
JournalInternational Journal of Cancer
Volume142
Issue number11
DOIs
StatePublished - Jun 1 2018

Fingerprint

Small Cell Lung Carcinoma
Lung Neoplasms
Messenger RNA
Survival Rate
Biomarkers
Hematologic Tests
Early Detection of Cancer
Reflex
Healthy Volunteers
Tomography
Clinical Trials
RNA
Sensitivity and Specificity
Equipment and Supplies
Polymerase Chain Reaction
Genes

Keywords

  • blood
  • early detection
  • FPR1
  • non-small cell lung cancer
  • small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Morris, S., Vachani, A., Pass, H. I., Rom, W. N., Ryden, K., Weiss, G. J., ... Mallery, D. W. (2018). Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer. International Journal of Cancer, 142(11), 2355-2362. https://doi.org/10.1002/ijc.31245

Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer. / Morris, Scott; Vachani, Anil; Pass, Harvey I.; Rom, William N.; Ryden, Kirk; Weiss, Glen J.; Hogarth, D. K.; Runger, George; Richards, Donald; Shelton, Troy; Mallery, David W.

In: International Journal of Cancer, Vol. 142, No. 11, 01.06.2018, p. 2355-2362.

Research output: Contribution to journalArticle

Morris, S, Vachani, A, Pass, HI, Rom, WN, Ryden, K, Weiss, GJ, Hogarth, DK, Runger, G, Richards, D, Shelton, T & Mallery, DW 2018, 'Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer', International Journal of Cancer, vol. 142, no. 11, pp. 2355-2362. https://doi.org/10.1002/ijc.31245
Morris, Scott ; Vachani, Anil ; Pass, Harvey I. ; Rom, William N. ; Ryden, Kirk ; Weiss, Glen J. ; Hogarth, D. K. ; Runger, George ; Richards, Donald ; Shelton, Troy ; Mallery, David W. / Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer. In: International Journal of Cancer. 2018 ; Vol. 142, No. 11. pp. 2355-2362.
@article{3a613afafdd54a28a3e62b21e8bceea5,
title = "Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer",
abstract = "While long-term survival rates for early-stage lung cancer are high, most cases are diagnosed in later stages that can negatively impact survival rates. We aim to design a simple, single biomarker blood test for early-stage lung cancer that is robust to preclinical variables and can be readily implemented in the clinic. Whole blood was collected in PAXgene tubes from a training set of 29 patients, and a validation set of 260 patients, of which samples from 58 patients were prospectively collected in a clinical trial specifically for our study. After RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay. Elevated levels of FPR1 mRNA in whole blood predicted lung cancer status with a sensitivity of 55{\%} and a specificity of 87{\%} on all validation specimens. The prospectively collected specimens had a significantly higher 68{\%} sensitivity and 89{\%} specificity. Results from patients with benign nodules were similar to healthy volunteers. No meaningful correlation was present between our test results and any clinical characteristic other than lung cancer diagnosis. FPR1 mRNA levels in whole blood can predict the presence of lung cancer. Using this as a reflex test for positive lung cancer screening computed tomography scans has the potential to increase the positive predictive value. This marker can be easily measured in an automated process utilizing off-the-shelf equipment and reagents. Further work is justified to explain the source of this biomarker.",
keywords = "blood, early detection, FPR1, non-small cell lung cancer, small cell lung cancer",
author = "Scott Morris and Anil Vachani and Pass, {Harvey I.} and Rom, {William N.} and Kirk Ryden and Weiss, {Glen J.} and Hogarth, {D. K.} and George Runger and Donald Richards and Troy Shelton and Mallery, {David W.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1002/ijc.31245",
language = "English (US)",
volume = "142",
pages = "2355--2362",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer

AU - Morris, Scott

AU - Vachani, Anil

AU - Pass, Harvey I.

AU - Rom, William N.

AU - Ryden, Kirk

AU - Weiss, Glen J.

AU - Hogarth, D. K.

AU - Runger, George

AU - Richards, Donald

AU - Shelton, Troy

AU - Mallery, David W.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - While long-term survival rates for early-stage lung cancer are high, most cases are diagnosed in later stages that can negatively impact survival rates. We aim to design a simple, single biomarker blood test for early-stage lung cancer that is robust to preclinical variables and can be readily implemented in the clinic. Whole blood was collected in PAXgene tubes from a training set of 29 patients, and a validation set of 260 patients, of which samples from 58 patients were prospectively collected in a clinical trial specifically for our study. After RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay. Elevated levels of FPR1 mRNA in whole blood predicted lung cancer status with a sensitivity of 55% and a specificity of 87% on all validation specimens. The prospectively collected specimens had a significantly higher 68% sensitivity and 89% specificity. Results from patients with benign nodules were similar to healthy volunteers. No meaningful correlation was present between our test results and any clinical characteristic other than lung cancer diagnosis. FPR1 mRNA levels in whole blood can predict the presence of lung cancer. Using this as a reflex test for positive lung cancer screening computed tomography scans has the potential to increase the positive predictive value. This marker can be easily measured in an automated process utilizing off-the-shelf equipment and reagents. Further work is justified to explain the source of this biomarker.

AB - While long-term survival rates for early-stage lung cancer are high, most cases are diagnosed in later stages that can negatively impact survival rates. We aim to design a simple, single biomarker blood test for early-stage lung cancer that is robust to preclinical variables and can be readily implemented in the clinic. Whole blood was collected in PAXgene tubes from a training set of 29 patients, and a validation set of 260 patients, of which samples from 58 patients were prospectively collected in a clinical trial specifically for our study. After RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay. Elevated levels of FPR1 mRNA in whole blood predicted lung cancer status with a sensitivity of 55% and a specificity of 87% on all validation specimens. The prospectively collected specimens had a significantly higher 68% sensitivity and 89% specificity. Results from patients with benign nodules were similar to healthy volunteers. No meaningful correlation was present between our test results and any clinical characteristic other than lung cancer diagnosis. FPR1 mRNA levels in whole blood can predict the presence of lung cancer. Using this as a reflex test for positive lung cancer screening computed tomography scans has the potential to increase the positive predictive value. This marker can be easily measured in an automated process utilizing off-the-shelf equipment and reagents. Further work is justified to explain the source of this biomarker.

KW - blood

KW - early detection

KW - FPR1

KW - non-small cell lung cancer

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85045273420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045273420&partnerID=8YFLogxK

U2 - 10.1002/ijc.31245

DO - 10.1002/ijc.31245

M3 - Article

VL - 142

SP - 2355

EP - 2362

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -